Publications by authors named "D Stroyakovskii"

Claim this Profile
A
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
J Crown, D Stroyakovskii, D A Yardley, C-S Huang, P A Fasching

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Antoinette R Tan, Seock-Ah Im, André Mattar, Ramon Colomer, Daniil Stroyakovskii

Lancet Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Justin Stebbing, Yauheni Baranau, Valeriy Baryash, Alexey Manikhas, Vladimir Moiseyenko, Daniil Stroyakovskii

Lancet Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis